Navigating Precision Oncology: Insights from an Integrated Clinical Data and Biobank Repository Initiative across a Network Cancer Program

Simple Summary In order to advance cancer research and personalized care, the Allegheny Health Network Cancer Institute (AHNCI) established a clinical data program (CDP) consisting of a comprehensive biobank and data repository. This includes details on socio-demographic characteristics, diagnosis, tumor characteristics, treatments, and prognosis. By understanding individual patient characteristics, such as genetics, lifestyle, and environmental factors, researchers can determine more effective treatments and preventive interventions. The CDP aids in predicting therapy responses and clinical outcomes through the utilization of cancer-related biomarkers across various disease sites. The CDP supports the initiative by providing comprehensive patient information, such as demographic characteristics, diagnosis details, and treatment responses, which, when combined with genomic data, can enhance the understanding of disease progression and treatment outcomes, thereby facilitating personalized care and precision medicine.Abstract Advancing cancer treatment relies on the rapid translation of new scientific discoveries to patient care. To facilitate this, an oncology biobank and data repository program, also referred to as the "Moonshot" program, was launched in 2021 within the Integrated Network Cancer Program of the Allegheny Health Network. A clinical data program (CDP) and biospecimen repository were established, and patient data and blood and tissue samples have been collected prospectively. To date, the study has accrued 2920 patients, predominantly female (61%) and Caucasian (90%), with a mean age of 64 +/- 13 years. The most common cancer sites were the endometrium/uterus (12%), lung/bronchus (12%), breast (11%), and colon/rectum (11%). Of patients diagnosed with cancer, 34% were diagnosed at stage I, 25% at stage II, 26% at stage III, and 15% at stage IV. The CDP is designed to support our initiative in advancing personalized cancer research by providing a comprehensive array of patient data, encompassing demographic characteristics, diagnostic details, and treatment responses. The "Moonshot" initiative aims to predict therapy responses and clinical outcomes through cancer-related biomarkers. The CDP facilitates this initiative by fostering data sharing, enabling comparative analyses, and informing the development of novel diagnostic and therapeutic methods.